An Important Announcement from BioCryst Pharmaceuticals

BioCryst launches Phase 1 trial for FOP

The IFOPA is pleased to share this news from BioCryst Pharmaceuticals about the launch of their Phase 1 First-in-Humans trial for BCX9250, an oral ALK-2 Inhibitor for FOP. Visit BioCryst's website to learn more.

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter